Drug Information

Drug General Information
Drug ID
D0T7BV
Former ID
DIB018018
Drug Name
compound 2
Synonyms
compound 37 [PMID: 22468684]
Drug Type
Small molecular drug
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Clinical trial [531865], [532013]
Structure
Download
2D MOL
Formula
C33H44N4O4S
InChI
InChI=1S/C33H44N4O4S/c1-21(40-5)29(39)37-26(16-22-8-6-9-24(14-22)31-34-12-13-42-31)28(38)20-35-27-18-33(10-7-11-33)41-30-25(27)15-23(19-36-30)17-32(2,3)4/h6,8-9,12-15,19,21,26-28,35,38H,7,10-11,16-18,20H2,1-5H3,(H,37,39)/t21-,26+,27+,28-/m1/s1
InChIKey
IUSARDYWEPUTPN-OZBXUNDUSA-N
PubChem Compound ID
60202321
PubChem Substance ID
144221302, 163321879, 163346727, 163473509, 178103532, 228225633, 246041808
Target and Pathway
Target(s) Beta-secretase Target Info Inhibitor [532013]
References
Ref 531865Design and synthesis of potent, orally efficacious hydroxyethylamine derived beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012 Nov 8;55(21):9025-44.
Ref 532013Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived beta-secretase inhibitors. J Pharmacol Exp Ther. 2012 Nov;343(2):460-7.
Ref 532013Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived beta-secretase inhibitors. J Pharmacol Exp Ther. 2012 Nov;343(2):460-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.